Mankind Pharma Ltd

Mankind Pharma Limited has announced that its 35th Annual General Meeting (AGM) will be held on Tuesday, August 4, 2026, at 03:30 p.m. IST. The meeting will be conducted through Video Conferencing and Other Audio-Visual Means, in compliance with the Companies Act, 2013, and relevant circulars from the Ministry of Corporate Affairs and SEBI. The official Notice of the AGM, along with the Annual Report for the financial year 2025-26, will be dispatched to shareholders in due course. Further details will also be available on the company's website.

Mankind Pharma Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Mankind Pharma Limited has announced a strategic realignment of its human resources leadership. Mr. Nilesh Kulkarni has been appointed as the Head of Human Resource Functions for the Mankind Pharma Group and designated as a Senior Management Personnel (SMP). This change is part of an internal organizational restructuring. Concurrently, Mr. Prateek Dubey has transitioned to new roles and ceased to be an SMP. Mr. Kulkarni brings over 25 years of HR experience, including previous roles at Bharat Serums and Vaccines Ltd., Novo Nordisk, Roche, Novartis, and Sanofi. The changes are effective immediately.

Mankind Pharma Ltd announced that its wholly-owned subsidiary, Mankind Lifesciences Private Limited (MLS), has acquired the remaining 10% stake in Upakarma Ayurveda Private Limited from Kaushcorp Media LLP for ₹75 Lakhs. This acquisition, completed on June 2, 2026, makes Upakarma a wholly-owned subsidiary of MLS and a step-down wholly-owned subsidiary of Mankind Pharma. The move is expected to enhance operational efficiencies through streamlined processes. Upakarma Ayurveda operates in the Ayurvedic, herbal, and nutraceutical products sector.

Mankind Pharma Ltd announced its Q4FY26 and FY26 financial results, reporting an 11.8% YoY increase in revenue for Q4FY26, reaching ₹3,443 crore, and a 17.0% YoY increase for FY26, totaling ₹14,278 crore. The adjusted EBITDA margin for Q4FY26 stood at 27.1%, with a PAT margin of 16.2%. Domestic revenue grew by 13.4% in Q4FY26. For FY26, domestic revenue reached ₹12,217 crore, up 14.4% YoY, while exports increased by 34.5% YoY to ₹2,061 crore.

Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the realignment of security cover for Non-Convertible Debentures post redemption, re-appointed Mr. Satish Kumar Sharma as Whole-Time Director, and re-appointed M/s. M. K. Kulshrestha & Associates as Cost Auditors for FY27. Additionally, the board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited.

Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the realignment of security cover for Non-Convertible Debentures post redemption of ₹1,250 Crores. Additionally, Mr. Satish Kumar Sharma was re-appointed as Whole-Time Director for another 5 years, and M/s. M. K. Kulshrestha & Associates were re-appointed as Cost Auditors for FY 2026-27. The board noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective May 31, 2026, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited.

Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. They also approved the realignment of security cover for existing NCDs post redemption of ₹1,250 Crores, re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for another 5 years, and re-appointed M/s. M. K. Kulshrestha & Associates as Cost Auditors for FY 2026-27. The board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective May 31, 2026, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited. Executive Directors decided not to draw commission for FY 2025-26 to strengthen the company's cash position.

Mankind Pharma Ltd has scheduled a Board of Directors meeting on May 19, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board will also discuss the realignment of security cover for Non-Convertible Debentures (NCDs) following the redemption of ₹1,250 Crores NCDs on April 16, 2026. The trading window remains closed until May 21, 2026.

Mankind Pharma's Board of Directors approved the closure and winding up of its wholly-owned subsidiary, Mankind Pharma Lanka (Private) Limited, incorporated in Sri Lanka. This decision was made because changed regulatory requirements rendered the anticipated business objectives unviable. The company clarified that the subsidiary had no business operations and is not considered a material subsidiary, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.